These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30519337)

  • 1. ABO Blood Type Has No Impact on Survival in Patients with Epithelial Ovarian Cancer.
    Wang L; Yang Z; Liu Y; Wang YN; Guo JY; Wu QJ; Gong TT
    J Cancer; 2018; 9(23):4334-4340. PubMed ID: 30519337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Influence of the Time Interval between Surgery and Chemotherapy in Epithelial Ovarian Cancer.
    Liu XD; Liu Y; Gong TT; Guo JY; Wang YN; Wang L; Wu QJ; Jiao YS
    J Cancer; 2018; 9(22):4172-4178. PubMed ID: 30519317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of preoperative hyponatremia in patients with epithelial ovarian cancer.
    Guo JY; Gong TT; Yang Z; Liu Y; Wang L; Wang YN; Wu QJ
    J Cancer; 2019; 10(4):836-842. PubMed ID: 30854089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
    Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
    J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The relationship of preoperativelymphocyte-monocyte ratio and the clinicopathological characteristics and prognosis of patients with epithelial ovarian cancer].
    Yang HM; Lou G
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):676-680. PubMed ID: 28926896
    [No Abstract]   [Full Text] [Related]  

  • 7. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.
    Marchini S; Cavalieri D; Fruscio R; Calura E; Garavaglia D; Fuso Nerini I; Mangioni C; Cattoretti G; Clivio L; Beltrame L; Katsaros D; Scarampi L; Menato G; Perego P; Chiorino G; Buda A; Romualdi C; D'Incalci M
    Lancet Oncol; 2011 Mar; 12(3):273-85. PubMed ID: 21345725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ABO Blood Group is an Independent Prognostic Factor in Patients with Ovarian Cancer.
    Song Q; Wu JZ; Wang S; Chen ZB
    J Cancer; 2019; 10(26):6754-6760. PubMed ID: 31777605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: a systematic review and meta-analysis of observational studies.
    Yang Z; Gu JH; Guo CS; Li XH; Yang WC
    Oncotarget; 2017 Jul; 8(28):46414-46424. PubMed ID: 28423365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery.
    Paulsen T; Kærn J; Tropé C
    Gynecol Oncol; 2011 Jul; 122(1):83-8. PubMed ID: 21435701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Impact of ABO Blood Group on the Survival in Patients with Ovarian Cancer.
    Zhou J; Yang LC; He ZY; Li FY; Wu SG; Sun JY
    J Cancer; 2015; 6(10):970-5. PubMed ID: 26316893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood type, ABO genetic variants, and ovarian cancer survival.
    Cozzi GD; Levinson RT; Toole H; Snyder MR; Deng A; Crispens MA; Khabele D; Beeghly-Fadiel A
    PLoS One; 2017; 12(4):e0175119. PubMed ID: 28448592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival.
    Mardas M; Stelmach-Mardas M; Madry R
    Support Care Cancer; 2017 Mar; 25(3):795-800. PubMed ID: 27771784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of obesity on survival outcomes of women with advanced epithelial ovarian cancer in Lagos, Nigeria: a retrospective cohort study.
    Okunade KS; Akinmola OO; Adekanye TV; Packson A; Adelabu H; Thomas-Ogodo O; Okoro AC; Okoye C; Anorlu RI
    Ecancermedicalscience; 2024; 18():1743. PubMed ID: 39421179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study.
    Rungruang B; Miller A; Richard SD; Hamilton CA; Rodriguez N; Bookman MA; Maxwell GL; Krivak TC; Horowitz NS
    Gynecol Oncol; 2012 Jan; 124(1):53-8. PubMed ID: 22032836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The survival detriment of venous thromboembolism with epithelial ovarian cancer.
    Gunderson CC; Thomas ED; Slaughter KN; Farrell R; Ding K; Farris RE; Lauer JK; Perry LJ; McMeekin DS; Moore KN
    Gynecol Oncol; 2014 Jul; 134(1):73-7. PubMed ID: 24793732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer.
    Jiang J; Bo D; Chang X; Cheng H; Ye X; Cui H
    Int J Clin Exp Med; 2015; 8(11):21303-10. PubMed ID: 26885070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer.
    Zhou M; Li L; Wang X; Wang C; Wang D
    Cell Physiol Biochem; 2018; 46(1):178-186. PubMed ID: 29587273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival.
    Mascarenhas C; Lambe M; Bellocco R; Bergfeldt K; Riman T; Persson I; Weiderpass E
    Int J Cancer; 2006 Dec; 119(12):2907-15. PubMed ID: 16998830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.